MD2552G2 - Medicament in the form of suppository - Google Patents

Medicament in the form of suppository

Info

Publication number
MD2552G2
MD2552G2 MDA20040128A MD20040128A MD2552G2 MD 2552 G2 MD2552 G2 MD 2552G2 MD A20040128 A MDA20040128 A MD A20040128A MD 20040128 A MD20040128 A MD 20040128A MD 2552 G2 MD2552 G2 MD 2552G2
Authority
MD
Moldova
Prior art keywords
suppository
medicament
propolis
rectum
vitamin
Prior art date
Application number
MDA20040128A
Other languages
Romanian (ro)
Russian (ru)
Other versions
MD2552F1 (en
Inventor
Людмила РАЗБОРСКИ
Ион ШАПОВАЛ
Original Assignee
Людмила РАЗБОРСКИ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Людмила РАЗБОРСКИ filed Critical Людмила РАЗБОРСКИ
Priority to MDA20040128A priority Critical patent/MD2552G2/en
Publication of MD2552F1 publication Critical patent/MD2552F1/en
Publication of MD2552G2 publication Critical patent/MD2552G2/en

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

The invention refers to the pharmaceutical industry, in particular to the suppositories used for treatment of inflammatory processes in the rectum and urogenital system.Summary of the invention consists in that the medicament in the form of suppository contains phenolic compounds of propolis, oleic solution of vitamin E, glycerol, semisynthetic glycerides in the following component ratio, calculated for a suppository with the weight of 2,00 g:
MDA20040128A 2004-05-19 2004-05-19 Medicament in the form of suppository MD2552G2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20040128A MD2552G2 (en) 2004-05-19 2004-05-19 Medicament in the form of suppository

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20040128A MD2552G2 (en) 2004-05-19 2004-05-19 Medicament in the form of suppository

Publications (2)

Publication Number Publication Date
MD2552F1 MD2552F1 (en) 2004-09-30
MD2552G2 true MD2552G2 (en) 2005-06-30

Family

ID=33095718

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20040128A MD2552G2 (en) 2004-05-19 2004-05-19 Medicament in the form of suppository

Country Status (1)

Country Link
MD (1) MD2552G2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2498810C1 (en) * 2012-05-10 2013-11-20 Государственное автономное учреждение Республики Башкортостан "Центр аграрных исследований" Antioxidant preparation with 5-aminosalicylic acid, quercetin and propolis extract

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2225213C2 (en) * 2002-03-04 2004-03-10 Пятигорская государственная фармацевтическая академия Suppository "apiprost" eliciting wound-healing effect

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2225213C2 (en) * 2002-03-04 2004-03-10 Пятигорская государственная фармацевтическая академия Suppository "apiprost" eliciting wound-healing effect

Also Published As

Publication number Publication date
MD2552F1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
BRPI0717845A2 (en) Use of compounds, pharmaceutical compositions and methods for the treatment and / or prophylaxis of diseases that can be treated with HDL-cholesterol elevating agents and compounds.
MX366119B (en) Methods for treating conditions associated with masp-2 dependent complement activation.
EP2377528A3 (en) Fatty acid metabolism inhibitors for use in the treatment of cancer
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
SG170826A1 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
GB9807639D0 (en) Anti-inflammatory agents
AR054255A1 (en) TREATMENT OF INTESTINAL DYSFUNCTION IN HIV PATIENTS
NZ587088A (en) Treatment of metastatic stage prostate cancer with degarelix
MY173616A (en) Compositions and methods for lowering triglycerides
CL2008001626A1 (en) Compounds derived from fused heterocycles, a pharmaceutical agent that comprises them and their use in the prophylaxis and treatment of cancer.
MY158162A (en) 5-membered heterocycle-based p38 kinase inhibitors
CL2008001782A1 (en) Use of a composition comprising a compound derived from heterocycle to treat or prevent the loss of intestinal flow; composition comprising said compound; and kit that includes the composition.
HK1132175A1 (en) Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
MX2021004999A (en) Administration of butyrate, bete-hydroxybutyrate, cannabidiol, and related compounds in humans.
NZ577393A (en) Use of 3-alpha-androstanediol, optionally in combination with a pde5 inhibitor, in the treatment of sexual dysfunction
CL2008003057A1 (en) Pharmaceutical combination comprising a purine derivative and a corticosteroid, beta-2 adrenoceptor agonist, antimuscarinic agent, among others; pharmaceutical composition; and its use to treat inflammatory or obstructive airway diseases.
MXPA02002681A (en) Use of g(a)-linolenic acid metabolites in the manufacture of a medicament for the treatment or prevention of cancer.
MY172984A (en) Use of lactobacillus rhamnosus gg in combination with a long chain polyunsaturated fatty acid for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
MX2009012920A (en) Compounds with 7-member cycle and the pharmaceutical use thereof for preventing and treating diabetes and metabolism syndrome.
MXPA03008423A (en) Nicotinic receptor agonists for the treatment of inflammatory diseases.
BRPI0514600A (en) methods for manufacturing a compound, for purifying a compound, for treating an individual having a neoplastic condition, having squamous cell carcinoma, and having basal cell carcinoma, for reducing or preventing the occurrence of a neoplastic condition in an individual, and for the reduction of serum triglycerides in an individual, compound, and, pharmaceutical composition
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
PL1838716T3 (en) Olanzapine pamoate dihydrate
MD2552G2 (en) Medicament in the form of suppository
MX2010003591A (en) Mechanical protective layer for solid dosage forms.

Legal Events

Date Code Title Description
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees